P4 Diagnostix Acquires Assets of Strand Diagnostics (know error)
February 11, 2020
P4 Diagnostix announced the acquisition of the assets of Strand Diagnostics, the creator of the know error DNA specimen provenance testing system. P4 said it will resume testing, supplies and logistics for know error clients and immediately offer Strand's UroSeq assay to expand P4's molecular testing capabilities for urology and oncology customers.
- Buyers
- P4 Diagnostix
- Targets
- Strand Diagnostics
- Sellers
- Strand Diagnostics
- Industry
- Healthcare Services
- Location
- Indiana, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Labcorp Acquires Personal Genome Diagnostics (PGDx)
February 21, 2022
Healthcare Services
Labcorp completed its acquisition of Personal Genome Diagnostics (PGDx), a cancer genomics company that develops liquid biopsy and tissue-based NGS products. Labcorp paid $450 million in cash at closing plus up to $125 million in performance-based milestones to expand its oncology genomics and liquid biopsy capabilities and accelerate access to precision diagnostics for clinical care and trials.
-
Ginkgo Bioworks Acquires Proof Diagnostics
February 28, 2024
Biotechnology
Ginkgo Bioworks has acquired Proof Diagnostics to integrate Proof's OMEGA nuclease libraries and portable diagnostic technologies into Ginkgo’s gene therapy and genetic medicines platform. The deal expands Ginkgo’s gene editing toolkit and diagnostic capabilities to better serve customers developing programmable medicines and rapid detection systems.
-
Quest Diagnostics Acquires Haystack Oncology
April 27, 2023
Healthcare Services
Quest Diagnostics has agreed to acquire Haystack Oncology in an all-cash transaction valued at $300 million at closing plus up to $150 million in potential milestones. The acquisition adds Haystack's sensitive ctDNA-based minimal residual disease (MRD) liquid biopsy technology to Quest's oncology, genomics and pathology capabilities to expand clinical lab services for MRD testing beginning in 2024.
-
JMD Properties, Inc. Acquires Stella Diagnostics
September 2, 2020
Biotechnology
JMD Properties, Inc. announced the acquisition of Stella Diagnostics, LLC via a preferred stock transaction and will change its corporate name to Stella Diagnostics, Inc. The deal positions the public company to pivot into the molecular diagnostics / biotech sector to commercialize Stella’s oncology-focused assays for esophageal disease.
-
Eurobio Scientific Acquires GenDx (Genome Diagnostics B.V.)
October 4, 2022
Biotechnology
Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.
-
LabGenomics USA LLC Acquires QDx Pathology
September 5, 2023
Healthcare Services
LabGenomics USA LLC, a subsidiary of South Korea–based LabGenomics Co., Ltd., has acquired QDx Pathology, a U.S. clinical and molecular pathology laboratory. The deal, signed in August 2023, is intended to accelerate LabGenomics' entry and expansion into the North American diagnostics market by combining QDx's lab services with LabGenomics' NGS-based molecular diagnostics capabilities.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.